Azacitadine (AZA)

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Janssen Research & Development, LLC

Conditions

AMLFLT3 Gene MutationLeukemia, Myeloid, AcuteMyelodysplastic Neoplasms

Phase 1

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

RecruitingNCT06561880

Institute of Hematology & Blood Diseases Hospital, ChinaAML, FLT3 Gene Mutation

Start: 2024-10-08End: 2027-08-31Target: 66Updated: 2026-05-13

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

RecruitingNCT06651229

Janssen Research & Development, LLCLeukemia, Myeloid, Acute, Myelodysplastic Neoplasms

Start: 2025-03-21End: 2028-11-21Target: 155Updated: 2026-05-08